Price Healthcare, Inc.

Pricing Provides VENDAJETM Reimbursement in All MAC Regions POMPANO BEACH, FLORIDA., Jan. 24, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, announced that the Center for Medicare Services (“CMS”) has established national pricing of VENDAJETM in all Medicare Administrative Contractors (MAC) regions, effective January 1, 2023. Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “This is a big accomplishment for BioStem Technologies and an added benefit for Medicare patients across the United States. Prior to this milestone, reimbursement for VENDAJETM was restricted to certain MAC regions. Now we will be able to offer VENDAJETM to all Medicare providers across the United States. VENDAJETM allografts now offers healthcare providers and their Medicare beneficiary patients a proven effective, reimbursable treatment option for lower extremity non-healing wounds. This accelerates our momentum as we expand availability of VENDAJETM to even more patients, thereby increasing adoption and creating better patient outcomes.” On January 1, 2023 CMS established and published the national pricing data for reimbursement based on the Average Sales Price (“ASP”) of VENDAJETM. Establishing national pricing for VENDAJETM enables BioStem to offer its product to all Medicare providers across the U.S., streamlines the reimbursement process and potentially accelerates reimbursement payments in all MAC regions. Andrew Van Vurst, Chief Operating Officer of BioStem Technologies Inc. added, “This is a significant milestone in VENDAJE’s commercial launch and will provide a streamlined and efficient reimbursement process. To date, we are encouraged by the payer coverage and are dedicated to facilitating patient access to VENDAJETM. This step further accelerates the successful roll out of VENDAJETM, the only allograft available that leverages BioStem’s proprietary BioREtain processing technology.” Available by prescription through a health care provider in all 50 states, VENDAJE offers patients who are experiencing non-healing lower extremity wounds an advanced treatment option that acts as a protective barrier or covering to provide an optimal environment for wound healing and closure. Patients interested in learning more about VENDAJE allografts can visit www.vendaje.biostemtechnologies.com or speak with their local provider. About BioStem Technologies, Inc. (OTCQB: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain® processing method. BioRetain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJETM, VENDAJETM AC, and VENDAJETM OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. BioStem Technologies, Inc.Phone: 954-380-8342Website: http://www.biostemtechnologies.comEmail: info@biostemtech.comTwitter: @BSEM_TechFacebook: BioStem Technologies Investor and Media Relations:Russo Partners, LLCNic Johnson 12 West 27th Street, 4th FloorNew York, NY 10001T: 303-482-6405Nic.Johnson@russopartnersllc.com

NEW YORK, June 24, 2022 /PRNewswire/ -- The Global Medical Device Contract Manufacturing Market is expected to clock US$ ~178.3 billion by 2031 owing to the rising incidence of chronic diseases and the booming medical device market. According to a report published by Growth Plus Reports, titled " Medical Device Contract Manufacturing Market by Product Type [Diagnostic & Monitoring Devices and Therapeutic Devices], Services [Device Development & Manufacturing Services, Quality Management Services, and Final Goods Assembly Services], Application [Cardiovascular, Orthopedic, Diabetes, Pulmonary, Oncology, and Diagnostic Imaging] – Global Outlook & Forecast 2021-2031" the market was worth in ~US$ 60.6 billion in 2020 and will display a CAGR of 10.3% during the forecast period, 2021- 2031 Request a Sample Copy of the Research Report: Growth Factors The rapid spread of coronavirus disease (COVID-19) across almost every country worldwide, has resulted in severe outcomes, across all regions. The first case of COVID-19 was found in Dec 2019, and by the end of Dec 2020, the count has surged to more than 90.3 million globally. Therefore, several prominent players, government bodies and numerous organizations are making an effort to accelerate the identification of COVID-19-positive patients, predict symptoms and disease severity in patients, healthcare workers & other at-risk individuals in critical service sectors. For instance, in Oct 2020, SteriPack Group, a leading global contract manufacturer of medical and diagnostic devices, was awarded $852,000 grant from the Bill & Melinda Gates Foundation. The purpose of the grant was procurement of necessary equipment to fast-track production of critically required sterile nasal swabs for Covid-19 testing. The global medical device contract manufacturing market has been analyzed from four different perspectives – Product Type, Services, Application, and Region. Excerpts from 'By Application Segmentation' The global medical device contract manufacturing market has been segmented majorly into seven distinct categories depending on the application, viz:- Cardiovascular Orthopedic Diabetes Pulmonary Oncology Diagnostic Imaging Others (Urology, Gynecology, Etc.) The cardiovascular segment is expected to be the fastest growing application segment during the forecast period. The growth of the segment can be attributed to growing prevalence of cardiovascular diseases (CVDs) globally coupled with rising awareness among the people regarding regular monitoring of cardiac activity and early diagnosis of CVDs. Excerpts from 'By Region Segmentation' The global medical device contract manufacturing market has been segmented into North America Europe Asia Pacific The Rest of the World (RoW) North America is expected to command the largest share in the global medical device contract manufacturing market, followed by Asia Pacific, Europe & Rest of the World (RoW). Factors such as developed healthcare infrastructure, rising prevalence of chronic & acute diseases owing to changing lifestyle and significant investment & research in medical devices can be attributed for the growth of the market. Presence of prominent players in the region coupled with their continuous effort to launch technologically advanced products is also expected to propel the growth of the market. Speak to Analyst: Excerpts from 'Competitive Landscape' The prominent players operating in the global medical device contract manufacturing market are · Gerresheimer AG Integer Holdings Corporation West Pharmaceutical Services, Inc Benchmark Plexus Corp Celestica Inc NIPRO PHARMA CORPORATION Sanmina Corporation TE Connectivity FLEX LTD Among others Report Scope & Segmentation: Table of Contents 1. INTRODUCTION i.Market Ecosystem ii. Geographic Scope iii.Timeline Under Consideration a. Historical Years – 2018 & 2019 b. Base Year – 2020 c. Forecasted Years – 2021 to 2031 iv. Currency Used in the Report 2. RESEARCH METHODOLOGY i. Research Approach ii. Data Collection Methodology iii. Data Sources a. Secondary Sources b. Primary Sources iv. Market Estimation Approach a. Bottom Up b. Top Down v. Market Forecasting Model vi. Limitations and Assumptions 3. PREMIUM INSIGHTS i. Current Market Trend (COVID-19 Perspective) ii. Key Players & Their Competitive Positioning (2020) 4. MARKET DYNAMICS i. Drivers ii. Restraints/Challenges iii. Opportunities VALUE PROPOSITIONS RELATED TO THE REPORT: Powered with Complimentary Analyst Hours and Expert Interviews with Each Report Comprehensive quantitative and qualitative insights at segment and sub-segment level Covid 19 impact trends and perspective Granular insights at global/regional/country level Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment Blanket coverage on competitive landscape Winning imperatives Exhaustive coverage on 'Strategic Developments' registered by leading players of the market CUSTOMIZATION OPTIONS: Distributor Landscape Assessment Pricing Intelligence Customer Base Assessment Investment & Initiatives Analysis 'Business Profile' of Key Players Quickly buy this premium report now: About Us: Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020. Contact: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +91 96545 76783 Web: Follow Us: LinkedIn | Twitter Logo: SOURCE Growth Plus Reports

NEW YORK, June 9, 2022 /PRNewswire/ -- The Global Breast Imaging Market is expected to clock US$ ~ 8.46 billion by 2031 owing to the rising prevalence of breast cancer, growing awareness of early diagnosis, and the rising new product launches by players in the market. According to the latest report published by Growth Plus Reports, titled "Breast Imaging Market by Technology (Ionizing Technology and Non-Ionizing Technology), Materials (Hospitals & Clinics and Diagnostics Center)–Global Outlook & Forecast 2021-2031 "The Breast Imaging market was worth ~US$ 2.76 billion in 2020 and is expected to grow at a CAGR of 10.7% during the forecast period, 2021-2031 Get a sample PDF of this research report: Growth Engines Breast cancer is the second leading cause of death in women globally. The rising incidence of breast cancer, the rising awareness of early detection of breast cancer, and rising investments in the development of new imaging systems are some of the factors propelling the market growth. Companies in the market are focused on adopting various organic as well as inorganic strategies. For instance, in February 2021, SmartBreast Corporation formed a partnership with FoxSemicon Integrated Technologies, Inc. to manufacture molecular breast imaging (MBI) systems. FoxSemicon has invested in SmartBreast Corporation and will contract manufacturer two MBI systems acquired by SmartBreast i.e. the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. Such strategic partnerships or collaborations help the company to strengthen their foothold in the market. The global breast imaging market has been analyzed from three perspectives: Technology, End User, and Region. Restraints However, complications related to breast implants are expected to restrain the market growth to a certain extent. Common complications associated with breast implants include infection, chronic breast pain, rupturing or leaking of the implant, necrosis, and breast or nipple numbness. Furthermore, among the patients who had undergone reconstruction surgery, around 45% of patients with silicone gel implants and around 20% with saline implants underwent at least one additional operation within 3 years. Whereas, around 25% of patients with silicone implants and 8% of patients with saline implants removed their implants. Therefore, complications associated with implants and an increase in the overall cost due to these complications are expected to limit the growth of the market. Excerpts from 'By Technology Segmentation' Based on technology, the breast imaging market has been segmented into :- Ionizing Technology Non-Ionizing Technology The Ionizing technology segment is further bifurcated into mammography, molecular breast imaging (MBI), positron emission tomography-computed tomography (PET-CT), positron emission mammography (PEM), and cone-beam computed tomography (CBCT). The mammography segment is further sub-segmented into 3D breast tomosynthesis, analog mammography, and full-field digital mammography (FFDM). The non-ionizing technology segment is further categorized as breast MRI, breast ultrasound, automated whole-breast ultrasound (AWBU), breast thermography, optical imaging, and electric impedance tomography. The non-ionizing breast imaging segment is anticipated to grow at the highest CAGR during the projected period. The advantages offered by these imaging technologies compared to ionizing breast imaging systems such as higher sensitivity, relatively low cost, and easy accessibility are some of the factors that are expected to increase the adoption of these systems in the coming years. Moreover, technological advancements and new product launches are fueling the growth of this segment. Ask here for more customization [email protected] Excerpts from 'By Region Segmentation' Regionally, the global breast imaging market has been segmented into North America Europe Asia Pacific The Rest of the World (RoW). North America held the largest share of the global breast imaging market in 2020. The growing old age population, the rising incidence of breast cancer, and higher awareness among the population regarding early diagnosis of breast cancer are some of the factors driving the market growth in this region. Moreover, a favorable reimbursement scenario for breast imaging is further boosting the breast imaging market growth in this region. Excerpts from 'Competitive Landscape' Some of the prominent players operating in the global breast imaging market include: - General Electric Company Hologic, Inc Siemens Healthcare Koninklijke Philips N.V Fujifilm Corporation Planmed OY Canon Medical Systems Dilon Medical Technologies, Inc Aurora Healthcare US Corp Delphinus Medical Technologies, Inc Among others Table Of Contents 1 INTRODUCTION 1.1 Market Ecosystem 1.2 Geographic Scope 1.3 Timeline Under Consideration • Historical Years – 2018 & 2019 • Base Year – 2020 • Forecasted Years – 2021 to 2031 1.4 Currency Used in the Report 2 RESEARCH METHODOLOGY 2.1 Research Approach 2.2 Data Collection Methodology 2.3 Data Sources 2.3.1 Secondary Sources 2.3.2 Primary Sources 2.4 Market Estimation Approach 2.4.1 Bottom Up 2.4.2 Top Down 2.5 Market Forecasting Model 2.6 Limitations and Assumptions 3 PREMIUM INSIGHTS 3.1 Current Market Trend (COVID-19 Perspective) 3.2 Key Players & Their Competitive Positioning (2020) 4 MARKET DYNAMICS 4.1 Drivers 4.2 Restraints/Challenges 4.3 Opportunities 5 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY IMPLANT TYPE 5.1 Silicone Implant 5.2 Saline Implant 6 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY APPLICATION 6.1 Breast Reconstruction 6.2 Breast Augmentation 7 GLOBAL BREAST IMPLANTS MARKET - ANALYSIS & FORECAST, BY END USER 7.1 Hospitals 7.2 Cosmetology Clinics 7.3 Others (Ambulatory Care Center, Etc.) TOC Continued… VALUE PROPOSITIONS RELATED TO THE REPORT: Powered with Complimentary Analyst Hours and Expert Interviews with Each Report Comprehensive quantitative and qualitative insights at segment and sub-segment level Covid 19 impact trends and perspective Granular insights at global/regional/country level Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment Blanket coverage on competitive landscape Winning imperatives Exhaustive coverage on 'Strategic Developments' registered by leading players of the market CUSTOMIZATION OPTIONS: Distributor Landscape Assessment Pricing Intelligence Customer Base Assessment Investment & Initiatives Analysis 'Business Profile' of Key Players Buy this Premium Research Report at About Us: Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020. Contact: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +91 96545 76783 Web: Follow Us: LinkedIn | Twitter SOURCE Growth Plus Reports